Lilly and Novo Nordisk's denials of 340B drug discounts when covered entities use contract pharmacies are each causing entities to lose more than $62 million per month on average in 340B program savings, the government says.

DOJ Says Lilly and Novo Nordisk’s 340B Actions Cost Providers Over $125 Million a Month and Hurt Patients

Drug manufacturers Eli Lilly and Novo Nordisk’s denials of 340B drug discounts when covered entities use contract pharmacies are causing entities to lose more than a combined total of $125 million per month in 340B program savings, federal filings in lawsuits over the companies’ actions show.

Hospitals, health centers, and clinics are losing a total combined average of $62.3 million per month in 340B program savings due to Lilly’s denials of 340B pricing when drugs are shipped to contract pharmacies, the government said in a June 25 motion in Lilly’s lawsuit. Lilly’s policy applies to all covered entity types.

Drug manufacturers Eli Lilly and Novo Nordisk’s denials of 340B drug discounts when covered entities use contract pharmacies are causing entities to lose more than a combined total of $125 million per month in 340B program savings, federal filings in lawsuits over the companies’ actions show.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report